SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a scientific stage biopharmaceutical firm growing modern proprietary medicines to deal with vital unmet wants in oncology with a concentrate on breast most cancers, at this time proclaims a strategic, sponsored analysis settlement with Weill Cornell Drugs to check the potential of inducing estrogen receptor (ER) expression in triple-negative breast most cancers (TNBC). The objective of this analysis is to find out if treating TNBC with extracellular vesicles carrying the ER will convert the tumor to ER+ and render it delicate to remedy with Selective Estrogen Receptor Modulators (SERM), together with Atossa’s proprietary (Z)-endoxifen.
The analysis challenge might be led by David Lyden, M.D., Ph.D., the Stavros S. Niarchos Professor in Pediatric Cardiology and Director of the Division of Pediatrics’ Doctor Scientist Coaching Program at Weill Cornell Drugs. Dr. Lyden’s laboratory is targeted on the molecular pathways activated by tumor extracellular vesicle uptake on the metastatic web site and figuring out potential therapeutic targets to thwart metastasis. His work has led to a brand new understanding of how main tumor cells dictate their very own metastases, by decoding how cancer-derived extracellular vesicles mediate intercellular communication. Most just lately, Dr. Lyden has recognized particular extracellular vesicle subpopulations and found a brand new subset of particles often known as exomeres, which collectively have distinct practical roles within the systemic results of most cancers.
“We sit up for working with Atossa and assume this challenge might present proof of precept for novel approaches to estrogen receptor reinduction in triple unfavorable breast most cancers,” mentioned Dr. Lyden. “If we’re capable of change the most cancers phenotype and activate the estrogen receptor, we might then deal with these sufferers with hormone remedy, which is simpler than at the moment authorised remedies for triple-negative breast most cancers.”
“Triple-negative breast most cancers grows and spreads quicker than different types of breast most cancers, disproportionately impacts Black and Hispanic ladies and has the next threat of recurrence,” mentioned Dr. Steven Quay, Atossa’s President and Chief Govt Officer. “It’s known as triple-negative breast most cancers as a result of it doesn’t have any of the receptors which are generally present in most breast cancers. This makes triple-negative breast most cancers notably tough to deal with as a result of medicine that focus on estrogen, progesterone, or the human epidermal development issue protein are ineffective. Activating the estrogen receptor and changing the tumor to ER+ would basically rework the remedy paradigm for these sufferers.”
About Triple-Adverse Breast Most cancers
Triple-negative breast most cancers (TNBC) accounts for about 10-15% of all breast cancers, which quantities to nearly 200,000 circumstances worldwide annually. The time period triple-negative breast most cancers refers to the truth that the most cancers cells don’t have estrogen or progesterone receptors (ER or PR) and likewise don’t make any or a lot of the human epidermal development issue receptor 2 (HER2) protein. The tumor cells check “unfavorable” on all three exams. These cancers are typically extra frequent in ladies who’re youthful than age 40, are Black or Hispanic, or who’ve a BRCA1 mutation. TNBC differs from different varieties of invasive breast most cancers in that it tends to develop and unfold quicker, has fewer remedy choices, has the next threat of recurrence, and tends to have a worse prognosis.
(Z)-endoxifen is probably the most lively metabolite of the FDA authorised Selective Estrogen Receptor Modulator (SERM), tamoxifen. Research by others have demonstrated that the therapeutic results of tamoxifen are pushed in a concentration-dependent method by (Z)-endoxifen. Along with its potent anti-estrogen results, (Z)-endoxifen at greater concentrations has been proven to focus on PKCβ1, a recognized oncogenic protein.
Atossa is growing a proprietary oral formulation of (Z)-endoxifen that doesn’t require liver metabolism to attain therapeutic concentrations and is encapsulated to bypass the abdomen as acidic circumstances within the abdomen convert a better proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa’s (Z)-endoxifen has been proven to be effectively tolerated in Section 1 research and in a small Section 2 research of ladies with breast most cancers. We’re at the moment finding out (Z)-endoxifen in three Section 2 research: one in wholesome ladies with measurable breast density and two different research together with the EVANGELINE research in ladies with ER+/HER2- breast most cancers. Atossa’s (Z)-endoxifen is protected by three issued U.S. patents and quite a few pending patent purposes.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm growing modern medicines in areas of great unmet medical want in oncology with a concentrate on breast most cancers. For extra data, please go to www.atossatherapeutics.com.
Eric Van Zanten
VP, Investor and Public Relations
FORWARD LOOKING STATEMENTS
Ahead-looking statements on this press launch, which Atossa undertakes no obligation to replace, are topic to dangers and uncertainties which will trigger precise outcomes to vary materially from the anticipated or estimated future outcomes, together with the dangers and uncertainties related to any variation between interim and ultimate scientific outcomes, actions and inactions by the FDA, the end result or timing of regulatory approvals wanted by Atossa together with these wanted to start research of (Z)-endoxifen, decrease than anticipated fee of affected person enrollment, estimated market dimension of medication underneath growth, the protection and efficacy of Atossa’s merchandise, efficiency of scientific analysis organizations and investigators, obstacles ensuing from proprietary rights held by others reminiscent of patent rights, whether or not discount in breast density or in Ki-67 or another outcome from a neoadjuvant research is an approvable endpoint for (Z)-endoxifen, whether or not Atossa can full acquisitions, and different dangers detailed occasionally in Atossa’s filings with the Securities and Change Fee, together with with out limitation its periodic stories on Type 10-Ok and 10-Q, every as amended and supplemented occasionally.